162 related articles for article (PubMed ID: 36971324)
1. Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
Taylor P; Rajendram R; Hanna S; Wilson V; Pell J; Li C; Cook A; Gattamaneni R; Plowman N; Jackson S; Hills R; French R; Uddin JM; Lee RWJ; Dayan CM
J Clin Endocrinol Metab; 2023 Sep; 108(10):2615-2625. PubMed ID: 36971324
[TBL] [Abstract][Full Text] [Related]
2. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
4. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
[TBL] [Abstract][Full Text] [Related]
5. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
7. Thyroid surgery for Graves' disease and Graves' ophthalmopathy.
Liu ZW; Masterson L; Fish B; Jani P; Chatterjee K
Cochrane Database Syst Rev; 2015 Nov; (11):CD010576. PubMed ID: 26606533
[TBL] [Abstract][Full Text] [Related]
8. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
9. Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy.
Nassar MM; Dickinson AJ; Neoh C; Powell C; Buck D; Galal E; Clarke MP
J AAPOS; 2009 Jun; 13(3):236-40. PubMed ID: 19395292
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
12. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features of Graves' Ophthalmopathy and Impact of Enalapril on the Course of Mild Graves' Ophthalmopathy: A Pilot Study.
Ataabadi G; Dabbaghmanesh MH; Owji N; Bakhshayeshkaram M; Montazeri-Najafabady N
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):139-148. PubMed ID: 31345156
[TBL] [Abstract][Full Text] [Related]
14. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of orbital fat decompression in Graves' orbitopathy.
Cheng AM; Wei YH; Tighe S; Sheha H; Liao SL
Br J Ophthalmol; 2018 Jan; 102(1):69-73. PubMed ID: 28450378
[TBL] [Abstract][Full Text] [Related]
16. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
[TBL] [Abstract][Full Text] [Related]
17. Quality of life of patients with thyroid eye disease: 3-year follow-up in a multidisciplinary clinic in Israel.
Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):2009-2015. PubMed ID: 33528651
[TBL] [Abstract][Full Text] [Related]
18. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
Taylor PN; Zhang L; Lee RWJ; Muller I; Ezra DG; Dayan CM; Kahaly GJ; Ludgate M
Nat Rev Endocrinol; 2020 Feb; 16(2):104-116. PubMed ID: 31889140
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]